Zymeworks (ZYME) Cash & Current Investments (2021 - 2026)
Zymeworks recorded quarterly Cash & Current Investments of $364.7 million in Q1 2026, up 59.41% quarter-over-quarter from $228.8 million in Q4 2025, and up 37.48% year-over-year from $265.3 million in Q1 2025.
Zymeworks' Cash & Current Investments history runs 6 years deep, the most recent figure standing at $364.7 million for Q1 2026.
- In Q1 2026, Cash & Current Investments rose 37.48% year-over-year to $364.7 million; the TTM figure through Mar 2026 stood at $364.7 million (up 37.48% YoY), while the FY2025 annual figure was $228.8 million, up 1.34% from the prior year.
- Cash & Current Investments came in at $364.7 million for Q1 2026 at Zymeworks, up from $228.8 million in the prior quarter.
- In the past five years, Cash & Current Investments ranged from a high of $492.2 million in Q4 2022 to a low of $166.2 million in Q3 2022.
- A 5-year average of $306.6 million and a median of $297.2 million in 2024 frame the typical range for Cash & Current Investments.
- Across the five-year window, Cash & Current Investments surged 94.86% in 2022 and tumbled 39.68% in 2024, its largest moves.
- Zymeworks' Cash & Current Investments stood at $492.2 million in 2022, then retreated by 23.95% to $374.3 million in 2023, then sank by 39.68% to $225.8 million in 2024, then climbed by 1.34% to $228.8 million in 2025, then soared by 59.41% to $364.7 million in 2026.
- According to Business Quant data, Cash & Current Investments over the past three periods registered $364.7 million, $228.8 million, and $251.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 2.13 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 32.30 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 286.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 61.46 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 2.77 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 7.25 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 18.44 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 8.75 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 3.01 Bn |
| 10 | Zymeworks | 1.84 Bn | 1.47 Bn | - | 364.73 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 364.73 Mn |
| Dec 31, 2025 | 228.80 Mn |
| Sep 30, 2025 | 251.93 Mn |
| Jun 30, 2025 | 281.38 Mn |
| Mar 31, 2025 | 265.29 Mn |
| Dec 31, 2024 | 225.78 Mn |
| Sep 30, 2024 | 297.20 Mn |
| Jun 30, 2024 | 330.15 Mn |
| Mar 31, 2024 | 345.05 Mn |
| Dec 31, 2023 | 374.33 Mn |
| Sep 30, 2023 | 295.41 Mn |
| Jun 30, 2023 | 340.09 Mn |
| Mar 31, 2023 | 340.79 Mn |
| Dec 31, 2022 | 492.23 Mn |
| Sep 30, 2022 | 166.24 Mn |
| Dec 31, 2021 | 252.61 Mn |